Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Beam Therapeutics Inc. on June 3, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Elections): All three Class III director nominees were elected to serve until the 2029 annual meeting.
- John Evans: 71,684,417 For; 864,042 Against; 256,889 Abstentions.
- John Maraganore, Ph.D.: 64,846,080 For; 7,701,591 Against; 257,677 Abstentions.
- Christi Shaw: 65,652,959 For; 6,893,102 Against; 259,287 Abstentions.
- Proposal 2 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Votes: 85,754,272 For; 165,746 Against; 304,989 Abstentions.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on an advisory basis.
- Votes: 71,546,749 For; 985,066 Against; 273,533 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote versus the sum of votes cast (For, Against, Abstentions) and Broker Non-Votes to assess shareholder participation rates.
- Note the significant "Against" votes for John Maraganore (approx. 10.5% of votes cast) and Christi Shaw (approx. 9.5% of votes cast) compared to John Evans (approx. 1.2% against).
- Confirm the term end date for the newly elected Class III directors is the 2029 annual meeting.
- Review the Definitive Proxy Statement filed on April 17, 2026, for detailed context on the director nominees and compensation plans.